il 37 rhil 37b rhil Search Results


90
Bio-Techne corporation recombinant human il-37b/il-1f7b protein, cf
Recombinant Human Il 37b/Il 1f7b Protein, Cf, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+37+rhil+37b+rhil/bio-techne+corporation___7585-il-cf?v=Bio-Techne+corporation
Average 90 stars, based on 1 article reviews
recombinant human il-37b/il-1f7b protein, cf - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

93
R&D Systems recombinant human il 37b rhil 37b
IL-37 treatment ameliorated EAE at both priming and ongoing phases. ( A ) C57BL/6 mice were immunized to induce EAE and treated i.p. with IL-37 (1 µg/ dose; n = 5) and PBS ( n = 4) at days 1, 4, and 7 p.i. The clinical scores were evaluated daily for 21 days p.i. Mean clinical scores for IL-37-treated and PBS-treated groups were calculated as the sum of daily scores for each mouse divided by the number of days per group. ( B-C ) EAE mice were treated i.p. with 1 µg of <t>rhIL-37b/</t> day when they showed the first symptoms of EAE. PBS was administered i.p. to the control group in the same way. Clinical scores were followed for 20 days p.i. (peak; n = 7 per group) ( B ) and 26 days p.i. (chronic; n = 4 per group) ( C ), and mean clinical scores were compared between IL-37-treated mice and control. Clinical scores were analyzed by multiple unpaired t-tests. Mean clinical scores were analyzed by Student’s t-test. Data shown as mean ± SEM. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. Ns: not significant
Recombinant Human Il 37b Rhil 37b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+37+rhil+37b+rhil/pmc11575187-29-0-4?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
recombinant human il 37b rhil 37b - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

94
R&D Systems human il 37b il 1f7b protein
IL-37 treatment ameliorated EAE at both priming and ongoing phases. ( A ) C57BL/6 mice were immunized to induce EAE and treated i.p. with IL-37 (1 µg/ dose; n = 5) and PBS ( n = 4) at days 1, 4, and 7 p.i. The clinical scores were evaluated daily for 21 days p.i. Mean clinical scores for IL-37-treated and PBS-treated groups were calculated as the sum of daily scores for each mouse divided by the number of days per group. ( B-C ) EAE mice were treated i.p. with 1 µg of <t>rhIL-37b/</t> day when they showed the first symptoms of EAE. PBS was administered i.p. to the control group in the same way. Clinical scores were followed for 20 days p.i. (peak; n = 7 per group) ( B ) and 26 days p.i. (chronic; n = 4 per group) ( C ), and mean clinical scores were compared between IL-37-treated mice and control. Clinical scores were analyzed by multiple unpaired t-tests. Mean clinical scores were analyzed by Student’s t-test. Data shown as mean ± SEM. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. Ns: not significant
Human Il 37b Il 1f7b Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+37+rhil+37b+rhil/pm32119739-40-138-142?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
human il 37b il 1f7b protein - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

92
R&D Systems recombinant human il 37b
IL-37 treatment ameliorated EAE at both priming and ongoing phases. ( A ) C57BL/6 mice were immunized to induce EAE and treated i.p. with IL-37 (1 µg/ dose; n = 5) and PBS ( n = 4) at days 1, 4, and 7 p.i. The clinical scores were evaluated daily for 21 days p.i. Mean clinical scores for IL-37-treated and PBS-treated groups were calculated as the sum of daily scores for each mouse divided by the number of days per group. ( B-C ) EAE mice were treated i.p. with 1 µg of <t>rhIL-37b/</t> day when they showed the first symptoms of EAE. PBS was administered i.p. to the control group in the same way. Clinical scores were followed for 20 days p.i. (peak; n = 7 per group) ( B ) and 26 days p.i. (chronic; n = 4 per group) ( C ), and mean clinical scores were compared between IL-37-treated mice and control. Clinical scores were analyzed by multiple unpaired t-tests. Mean clinical scores were analyzed by Student’s t-test. Data shown as mean ± SEM. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. Ns: not significant
Recombinant Human Il 37b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+37+rhil+37b+rhil/ppr0849330-40-0-6?v=R%26D+Systems
Average 92 stars, based on 1 article reviews
recombinant human il 37b - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier

90
Corning Life Sciences rhil-37b
IL-37 treatment ameliorated EAE at both priming and ongoing phases. ( A ) C57BL/6 mice were immunized to induce EAE and treated i.p. with IL-37 (1 µg/ dose; n = 5) and PBS ( n = 4) at days 1, 4, and 7 p.i. The clinical scores were evaluated daily for 21 days p.i. Mean clinical scores for IL-37-treated and PBS-treated groups were calculated as the sum of daily scores for each mouse divided by the number of days per group. ( B-C ) EAE mice were treated i.p. with 1 µg of <t>rhIL-37b/</t> day when they showed the first symptoms of EAE. PBS was administered i.p. to the control group in the same way. Clinical scores were followed for 20 days p.i. (peak; n = 7 per group) ( B ) and 26 days p.i. (chronic; n = 4 per group) ( C ), and mean clinical scores were compared between IL-37-treated mice and control. Clinical scores were analyzed by multiple unpaired t-tests. Mean clinical scores were analyzed by Student’s t-test. Data shown as mean ± SEM. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. Ns: not significant
Rhil 37b, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+37+rhil+37b+rhil/pm32119739-86-7-20?v=Corning+Life+Sciences
Average 90 stars, based on 1 article reviews
rhil-37b - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
R&D Systems il 37
IL-37 treatment ameliorated EAE at both priming and ongoing phases. ( A ) C57BL/6 mice were immunized to induce EAE and treated i.p. with IL-37 (1 µg/ dose; n = 5) and PBS ( n = 4) at days 1, 4, and 7 p.i. The clinical scores were evaluated daily for 21 days p.i. Mean clinical scores for IL-37-treated and PBS-treated groups were calculated as the sum of daily scores for each mouse divided by the number of days per group. ( B-C ) EAE mice were treated i.p. with 1 µg of <t>rhIL-37b/</t> day when they showed the first symptoms of EAE. PBS was administered i.p. to the control group in the same way. Clinical scores were followed for 20 days p.i. (peak; n = 7 per group) ( B ) and 26 days p.i. (chronic; n = 4 per group) ( C ), and mean clinical scores were compared between IL-37-treated mice and control. Clinical scores were analyzed by multiple unpaired t-tests. Mean clinical scores were analyzed by Student’s t-test. Data shown as mean ± SEM. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. Ns: not significant
Il 37, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+37+rhil+37b+rhil/pm33239358-63-64-78?v=R%26D+Systems
Average 90 stars, based on 1 article reviews
il 37 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

94
R&D Systems biotinylated recombinant human il 37b protein
IL-37 treatment ameliorated EAE at both priming and ongoing phases. ( A ) C57BL/6 mice were immunized to induce EAE and treated i.p. with IL-37 (1 µg/ dose; n = 5) and PBS ( n = 4) at days 1, 4, and 7 p.i. The clinical scores were evaluated daily for 21 days p.i. Mean clinical scores for IL-37-treated and PBS-treated groups were calculated as the sum of daily scores for each mouse divided by the number of days per group. ( B-C ) EAE mice were treated i.p. with 1 µg of <t>rhIL-37b/</t> day when they showed the first symptoms of EAE. PBS was administered i.p. to the control group in the same way. Clinical scores were followed for 20 days p.i. (peak; n = 7 per group) ( B ) and 26 days p.i. (chronic; n = 4 per group) ( C ), and mean clinical scores were compared between IL-37-treated mice and control. Clinical scores were analyzed by multiple unpaired t-tests. Mean clinical scores were analyzed by Student’s t-test. Data shown as mean ± SEM. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. Ns: not significant
Biotinylated Recombinant Human Il 37b Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+37+rhil+37b+rhil/pm32461183-92-13-19?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
biotinylated recombinant human il 37b protein - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

90
GemPharmatech Co Ltd hil-37b conditional knock-in mice
IL-37 treatment ameliorated EAE at both priming and ongoing phases. ( A ) C57BL/6 mice were immunized to induce EAE and treated i.p. with IL-37 (1 µg/ dose; n = 5) and PBS ( n = 4) at days 1, 4, and 7 p.i. The clinical scores were evaluated daily for 21 days p.i. Mean clinical scores for IL-37-treated and PBS-treated groups were calculated as the sum of daily scores for each mouse divided by the number of days per group. ( B-C ) EAE mice were treated i.p. with 1 µg of <t>rhIL-37b/</t> day when they showed the first symptoms of EAE. PBS was administered i.p. to the control group in the same way. Clinical scores were followed for 20 days p.i. (peak; n = 7 per group) ( B ) and 26 days p.i. (chronic; n = 4 per group) ( C ), and mean clinical scores were compared between IL-37-treated mice and control. Clinical scores were analyzed by multiple unpaired t-tests. Mean clinical scores were analyzed by Student’s t-test. Data shown as mean ± SEM. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. Ns: not significant
Hil 37b Conditional Knock In Mice, supplied by GemPharmatech Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+37+rhil+37b+rhil/pmc11127460-40-0-27?v=GemPharmatech+Co+Ltd
Average 90 stars, based on 1 article reviews
hil-37b conditional knock-in mice - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Enzo Biochem the human 20s proteasomes used for the degradation of mature forms of human il-1α, il-1β and il-37b
Number and frequency of peptide products identified and quantified in the 15 protein digestions by inSPIRE 1.5 - aSPIRE
The Human 20s Proteasomes Used For The Degradation Of Mature Forms Of Human Il 1α, Il 1β And Il 37b, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+37+rhil+37b+rhil/pmc10850103-363-16-20?v=Enzo+Biochem
Average 90 stars, based on 1 article reviews
the human 20s proteasomes used for the degradation of mature forms of human il-1α, il-1β and il-37b - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma human il-37b gene overexpression lentivirus
Number and frequency of peptide products identified and quantified in the 15 protein digestions by inSPIRE 1.5 - aSPIRE
Human Il 37b Gene Overexpression Lentivirus, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+37+rhil+37b+rhil/pm35046386-225-1-12?v=Shanghai+GenePharma
Average 90 stars, based on 1 article reviews
human il-37b gene overexpression lentivirus - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

92
Addgene inc addgene cat 26567
Number and frequency of peptide products identified and quantified in the 15 protein digestions by inSPIRE 1.5 - aSPIRE
Addgene Cat 26567, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+37+rhil+37b+rhil/pmc11169412-271-9-9?v=Addgene+inc
Average 92 stars, based on 1 article reviews
addgene cat 26567 - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier

Image Search Results


IL-37 treatment ameliorated EAE at both priming and ongoing phases. ( A ) C57BL/6 mice were immunized to induce EAE and treated i.p. with IL-37 (1 µg/ dose; n = 5) and PBS ( n = 4) at days 1, 4, and 7 p.i. The clinical scores were evaluated daily for 21 days p.i. Mean clinical scores for IL-37-treated and PBS-treated groups were calculated as the sum of daily scores for each mouse divided by the number of days per group. ( B-C ) EAE mice were treated i.p. with 1 µg of rhIL-37b/ day when they showed the first symptoms of EAE. PBS was administered i.p. to the control group in the same way. Clinical scores were followed for 20 days p.i. (peak; n = 7 per group) ( B ) and 26 days p.i. (chronic; n = 4 per group) ( C ), and mean clinical scores were compared between IL-37-treated mice and control. Clinical scores were analyzed by multiple unpaired t-tests. Mean clinical scores were analyzed by Student’s t-test. Data shown as mean ± SEM. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. Ns: not significant

Journal: Journal of Neuroinflammation

Article Title: IL-37 suppresses CNS autoimmunity by increasing the frequency of Treg cells and reducing CD4 + T cell-derived IL-10 production

doi: 10.1186/s12974-024-03295-1

Figure Lengend Snippet: IL-37 treatment ameliorated EAE at both priming and ongoing phases. ( A ) C57BL/6 mice were immunized to induce EAE and treated i.p. with IL-37 (1 µg/ dose; n = 5) and PBS ( n = 4) at days 1, 4, and 7 p.i. The clinical scores were evaluated daily for 21 days p.i. Mean clinical scores for IL-37-treated and PBS-treated groups were calculated as the sum of daily scores for each mouse divided by the number of days per group. ( B-C ) EAE mice were treated i.p. with 1 µg of rhIL-37b/ day when they showed the first symptoms of EAE. PBS was administered i.p. to the control group in the same way. Clinical scores were followed for 20 days p.i. (peak; n = 7 per group) ( B ) and 26 days p.i. (chronic; n = 4 per group) ( C ), and mean clinical scores were compared between IL-37-treated mice and control. Clinical scores were analyzed by multiple unpaired t-tests. Mean clinical scores were analyzed by Student’s t-test. Data shown as mean ± SEM. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. Ns: not significant

Article Snippet: Recombinant human IL-37b (rhIL-37b) (R&D Systems) was reconstituted in phosphate-buffered saline (PBS) at 200 μg/mL.

Techniques: Control

IL-37 enhanced MBP expression. ( A ) The lumbar section of the spinal cord was harvested from EAE mice treated with PBS (left) or rhIL-37b (middle) at the peak of disease ( n = 4 mice in each group). Naïve mice (right) are illustrated as a control to show healthy spinal cord. ( B ) Mean fluorescent intensity of MBP expression in both groups was measured using FIJI software. Unpaired t-test was performed to analyze these two groups. Data shown as mean ± SEM. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. Ns: not significant

Journal: Journal of Neuroinflammation

Article Title: IL-37 suppresses CNS autoimmunity by increasing the frequency of Treg cells and reducing CD4 + T cell-derived IL-10 production

doi: 10.1186/s12974-024-03295-1

Figure Lengend Snippet: IL-37 enhanced MBP expression. ( A ) The lumbar section of the spinal cord was harvested from EAE mice treated with PBS (left) or rhIL-37b (middle) at the peak of disease ( n = 4 mice in each group). Naïve mice (right) are illustrated as a control to show healthy spinal cord. ( B ) Mean fluorescent intensity of MBP expression in both groups was measured using FIJI software. Unpaired t-test was performed to analyze these two groups. Data shown as mean ± SEM. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. Ns: not significant

Article Snippet: Recombinant human IL-37b (rhIL-37b) (R&D Systems) was reconstituted in phosphate-buffered saline (PBS) at 200 μg/mL.

Techniques: Expressing, Control, Software

Number and frequency of peptide products identified and quantified in the 15 protein digestions by inSPIRE 1.5 - aSPIRE

Journal: Nature Communications

Article Title: Protein degradation by human 20S proteasomes elucidates the interplay between peptide hydrolysis and splicing

doi: 10.1038/s41467-024-45339-3

Figure Lengend Snippet: Number and frequency of peptide products identified and quantified in the 15 protein digestions by inSPIRE 1.5 - aSPIRE

Article Snippet: The human 20S proteasomes used for the degradation of mature forms of human IL-1α, IL-1β and IL-37b were purchased from Enzo Life Sciences (BML-PW8720-0050; see Supplementary Fig. ).

Techniques: